Matching Perfusion and Metabolic Activity in HFpEF
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study will test whether pharmacologic agents that increase perfusion [Potassium Nitrate
(KNO3)], with and without additional supplements that may improve mitochondrial function
[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)], improve submaximal exercise
endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants
with Heart Failure with Preserved Ejection Fraction (HFpEF).